Publications

5813 Results

The importance of patient-centered research in oncology clinical trials: motivation for the Monograph series

Authors
Pugh SL
Journal / Conference
J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):1-2. doi: 10.1093/jncimonographs/lgae052
Year
2025
Research Committee(s)
Cancer Care Delivery
PMID
PMID39989042
PMC
PMC11848026

Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163

Authors
Saba NF
Journal / Conference
Clin Cancer Res. 2025 Jun 13;31(12):2339-2346. doi: 10.1158/1078-0432.CCR-24-4085.NIHMS2075936
Year
2025
PMID
PMID40227186
PMC
PMC12165817

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Authors
Shanafelt TD
Journal / Conference
Blood Adv. 2025 Jan 14;9(1):224-228. doi: 10.1182/bloodadvances.2024013474
Year
2025
Research Committee(s)
Leukemia
PMID
PMID39163612
PMC
PMC11788128
Study Number(s)
CTSU/E1912

Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Authors
Tarhini AA
Journal / Conference
Clin Cancer Res. 2025 Aug 1;31(15):3249-3258. doi: 10.1158/1078-0432.CCR-24-3980. NIHMS2085262
Year
2025
Research Committee(s)
Melanoma
PMID
PMID40392969
PMC
PMC12316551
Study Number(s)
CTSU/E1609

CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists

Authors
Uehara Y
Journal / Conference
Cancer Immunol Immunother. 2025 Nov 3;74(12):359. doi: 10.1007/s00262-025-04197-8
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41182434
PMC
PMC12583269

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Authors
Wang X
Journal / Conference
Nat Commun. 2025 Nov 13;16(1):9968. doi: 10.1038/s41467-025-65016-3
Year
2025
Research Committee(s)
Melanoma
PMID
PMID41233329
PMC
PMC12615696
Study Number(s)
CTSU/E1609

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Authors
Zandberg DP
Journal / Conference
J Clin Oncol. 2025 Jul 20;43(21):2398-2408. doi: 10.1200/JCO-25-00759. Epub 2025 May 31.NIHMS2079170
Year
2025
PMID
PMID40448574
PMC
PMC12677393

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. Reply

Authors
Herrera AF
Journal / Conference
N Engl J Med. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID39752312
Study Number(s)
S1826

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Authors
A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;G Chatta;J Kim;M Bilen;B McGregor;P Singh;A Tripathi;S Cole;N Simon;S Niglio;L Ley;L Cordes;S Srinivas;J Huang;P Steen;M Odegaard;C Watt;D Petrylak;J Hoffman-Censits;Y Wen;O Hahn;C Mitchell;A Tan;H Streicher;E Sharon;H Moon;M Woods;S Halabi;G Burbano;M Morris;J Rosenberg
Journal / Conference
N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15.NIHMS2021479
Year
2025
Research Committee(s)
Genitourinary
PMID
PMID39282902
PMC
PMC11698643
Study Number(s)
CTSU/A031501

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Authors
E Bergsland;S Geyer;T Asmis;S Behr;P Kumthekar;M Maitland;D Niedzwiecki;A Nixon;L Schwartz;J Strosberg;A Venook;E O'Reilly;J Meyerhardt
Journal / Conference
J Clin Oncol. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3.NIHMS2099573
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID40902132
PMC
PMC12457709
Study Number(s)
CTSU/A021202